US20190314271A1 - Topical composition for the control of pain in animals - Google Patents
Topical composition for the control of pain in animals Download PDFInfo
- Publication number
- US20190314271A1 US20190314271A1 US16/302,628 US201716302628A US2019314271A1 US 20190314271 A1 US20190314271 A1 US 20190314271A1 US 201716302628 A US201716302628 A US 201716302628A US 2019314271 A1 US2019314271 A1 US 2019314271A1
- Authority
- US
- United States
- Prior art keywords
- meloxicam
- lidocaine
- gel
- topical
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 53
- 208000002193 Pain Diseases 0.000 title claims abstract description 50
- 230000036407 pain Effects 0.000 title claims abstract description 48
- 230000000699 topical effect Effects 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 229960001929 meloxicam Drugs 0.000 claims abstract description 134
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims abstract description 131
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 75
- 229960004194 lidocaine Drugs 0.000 claims abstract description 70
- 238000011282 treatment Methods 0.000 claims abstract description 33
- 239000003589 local anesthetic agent Substances 0.000 claims abstract description 16
- 230000000202 analgesic effect Effects 0.000 claims abstract description 10
- 239000000499 gel Substances 0.000 claims description 70
- 238000000034 method Methods 0.000 claims description 47
- 238000003032 molecular docking Methods 0.000 claims description 29
- 206010061218 Inflammation Diseases 0.000 claims description 17
- 230000004054 inflammatory process Effects 0.000 claims description 17
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 14
- 206010002091 Anaesthesia Diseases 0.000 claims description 12
- 230000037005 anaesthesia Effects 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 12
- 206010052428 Wound Diseases 0.000 claims description 10
- 241000282898 Sus scrofa Species 0.000 claims description 9
- 230000036592 analgesia Effects 0.000 claims description 9
- 208000027418 Wounds and injury Diseases 0.000 claims description 8
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 206010011732 Cyst Diseases 0.000 claims description 3
- 206010022524 Intentional self-injury Diseases 0.000 claims description 3
- 208000005560 Self Mutilation Diseases 0.000 claims description 3
- 229940035676 analgesics Drugs 0.000 claims description 3
- 239000000730 antalgic agent Substances 0.000 claims description 3
- 210000003323 beak Anatomy 0.000 claims description 3
- 208000031513 cyst Diseases 0.000 claims description 3
- 229960001259 diclofenac Drugs 0.000 claims description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 3
- 208000010801 foot rot Diseases 0.000 claims description 3
- 230000003370 grooming effect Effects 0.000 claims description 3
- 238000002513 implantation Methods 0.000 claims description 3
- 230000000116 mitigating effect Effects 0.000 claims description 3
- 238000009966 trimming Methods 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000007933 dermal patch Substances 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 238000010348 incorporation Methods 0.000 claims description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 claims 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 claims 1
- 229960003150 bupivacaine Drugs 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 229960001850 droxicam Drugs 0.000 claims 1
- OEHFRZLKGRKFAS-UHFFFAOYSA-N droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 claims 1
- 229960004945 etoricoxib Drugs 0.000 claims 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 claims 1
- 229960002524 firocoxib Drugs 0.000 claims 1
- FULAPETWGIGNMT-UHFFFAOYSA-N firocoxib Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OCC1CC1 FULAPETWGIGNMT-UHFFFAOYSA-N 0.000 claims 1
- 229960004369 flufenamic acid Drugs 0.000 claims 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims 1
- NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 claims 1
- 229960000588 flunixin Drugs 0.000 claims 1
- 229960002390 flurbiprofen Drugs 0.000 claims 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 1
- 229960000991 ketoprofen Drugs 0.000 claims 1
- 229960002202 lornoxicam Drugs 0.000 claims 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 229960003803 meclofenamic acid Drugs 0.000 claims 1
- 229960003464 mefenamic acid Drugs 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 229960004662 parecoxib Drugs 0.000 claims 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 claims 1
- 229960002895 phenylbutazone Drugs 0.000 claims 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- 229960001807 prilocaine Drugs 0.000 claims 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims 1
- 150000005599 propionic acid derivatives Chemical class 0.000 claims 1
- 229960002871 tenoxicam Drugs 0.000 claims 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 claims 1
- 229960002372 tetracaine Drugs 0.000 claims 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims 1
- 229960002905 tolfenamic acid Drugs 0.000 claims 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 claims 1
- 229940042129 topical gel Drugs 0.000 description 55
- 210000004706 scrotum Anatomy 0.000 description 31
- 210000001519 tissue Anatomy 0.000 description 23
- 241000282887 Suidae Species 0.000 description 19
- 210000003491 skin Anatomy 0.000 description 19
- 230000000638 stimulation Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 14
- 231100000703 Maximum Residue Limit Toxicity 0.000 description 12
- 230000006399 behavior Effects 0.000 description 12
- 238000002690 local anesthesia Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 9
- 229920002125 Sokalan® Polymers 0.000 description 9
- 230000003444 anaesthetic effect Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000007774 longterm Effects 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000002500 effect on skin Effects 0.000 description 8
- 230000029663 wound healing Effects 0.000 description 8
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 7
- 102100024304 Protachykinin-1 Human genes 0.000 description 7
- 101800003906 Substance P Proteins 0.000 description 7
- 229960000890 hydrocortisone Drugs 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 229940035674 anesthetics Drugs 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000013480 data collection Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000003193 general anesthetic agent Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 101100129915 Escherichia coli (strain K12) melB gene Proteins 0.000 description 3
- 208000015580 Increased body weight Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 229960005015 local anesthetics Drugs 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000000474 nursing effect Effects 0.000 description 3
- 206010033675 panniculitis Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000004304 subcutaneous tissue Anatomy 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 241000283903 Ovis aries Species 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 230000037374 absorbed through the skin Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 229960000942 diclofenac epolamine Drugs 0.000 description 2
- DCERVXIINVUMKU-UHFFFAOYSA-N diclofenac epolamine Chemical compound OCC[NH+]1CCCC1.[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCERVXIINVUMKU-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 229940001674 meloxicam 5 mg/ml Drugs 0.000 description 2
- 229940001676 metacam Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000006461 physiological response Effects 0.000 description 2
- 235000015277 pork Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 231100000057 systemic toxicity Toxicity 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000008791 toxic response Effects 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229940019097 EMLA Drugs 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940102884 adrenalin Drugs 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000669 biting effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 231100000060 cardiovascular toxicity Toxicity 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002692 epidural anesthesia Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940008949 lidocaine topical gel Drugs 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 229940045253 meloxicam oral suspension Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000013310 pig model Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 231100000732 tissue residue Toxicity 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- This invention relates to topical compositions and methods for treating animals in pain. This invention also relates to methods of treating pain associated with castration and tail docking.
- Castration and tail docking of piglets is a common management practice on commercial swine farms to prevent the occurrence of boar taint, aggressive behaviours and infections associated with tail chewing. These procedures can cause acute pain-induced stress which is an animal welfare concern, negative public perception concerning these procedures being performed without analgesia or anesthesia is growing.
- piglets undergo certain elective surgical procedures. Castration is performed to eliminate boar taint and improve the quality of meat. Tail docking is performed to reduce tail chewing which leads to infections, abscesses, morbidity and mortalities as well as condemnation of animals and meat. In Canada, approximately 15 million piglets undergo castration and 30 million tail docking.
- Example 1 Research by Hansson et al. (2011) evaluated the effect of local anesthesia and/or analgesia on pain responses induced by piglet castration. The results are shown in Example 1.
- lidocaine and meloxicam are effective in the pig model for both short and long term pain associated with castration, however the excessive handling required to administer two injections and the injections in themselves create a level of stress and pain for the animals. The excessive handling required to administer two injections and the injections in themselves create a level of stress and pain for the animals. Lidocaine is very acidic and causes significant pain when injected.
- Lidocaine is a common local anesthetic and class-1b antiarrhythmic drug. Lidocaine is used topically to relieve itching, burning, and pain from skin inflammations, injected as a dental anesthetic, or used as a local anesthetic for minor surgery. Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.
- NSAIDs non-steroidal anti-inflammatory drugs
- This invention provides a topical analgesic/anesthetic/anti-inflammatory product to control both short and long term pain in animals.
- the present invention is a topical analgesic/anesthetic/anti-inflammatory product to control both short and long term pain.
- Lidocam (4% lidocaine and 0.3% Meloxicam) was developed to address the animal welfare and production requirements by the Canadian swine industry.
- Lidocam is a topical gel containing 4% lidocaine base and 0.3% meloxicam that are able to rapidly penetrate into the skin and provide both short term local anesthesia and longer term control of pain and inflammation.
- This product is intended to address castration and tail docking in piglets. It also has other applications for the pork industry (e.g. Crate sores) and other food animal production.
- the product was shown to be effective in controlling pain and inflammation in piglets undergoing castration and tail docking.
- the use of the product had production economic benefits as piglets treated with the product had increased growth rates compared to untreated controls.
- the product was easy to administer and was shown to be safe to piglets even at 9 times the required dose. Tissue residue studies were conducted and it was shown that the active agents were eliminated from the meat and organs within 2 weeks.
- a topical lidocaine/meloxicam will provide to the industry a simple, inexpensive and effective solution to meet the Code of Practice for the Care and Handling of Pigs. There will be no need to inject animals whereby reducing animal stress and avoid needle stick injuries to staff.
- compositions and methods of the present invention show the ability to produce a topical gel for use in piglets that would be effective, safe, stable and could be sprayed onto the surgical site.
- Some embodiments of the invention also include livestock pharmaceutical products to address food producing animal's pain incurred during production procedures such as castration, tail docking, dehorning etc.
- This formulation has shown release of M and L to be 98 and 95% respectively.
- the amount of applied product that is absorbed through the skin for M and L is 58 and 52% respectively.
- Therapeutic levels are obtained within 30 minutes for L and one hour for M.
- Topical L and non-steroidal anti-inflammatory drugs (NSAIDs) such as M exist individually as commercial products and have been shown to be effective in humans, lambs and piglets but a combination would address short and long term pain.
- NSAIDs non-steroidal anti-inflammatory drugs
- the devices and methods of the present invention alleviate the above-described problems and, in addition, provide pain mitigation from other procedures including but not limited to: wound care, wound management, foot rot, dental procedures, cyst removal, de-horning, de-clawing, de-horning, de-beaking, beak trimming (including Infra-red procedures), branding, implantation of RFID or ear-tags, tattooing, microchipping, cannibalism, self-mutilation, grooming, reduced antibiotic treatments; increased growth rates; and reduced mortalities.
- the present invention involves a method of treating an animal for pain comprising administering a topical composition comprising an effective dose of a local anesthetic and an analgesic.
- the animal being treated is swine, more preferably pigs or piglets.
- the present invention also is a composition for the topical treatment of an animal comprising about 0.1% to about 1% meloxicam, preferably about 0.2% to about 0.4% meloxicam; and about 2% to about 7% lidocaine, preferably about 3% to about 5% lidocaine.
- Embodiments of the invention provide a new tool that will allow reduced pain and stress in castration and tail docking procedures, in a non-invasive manner (topical vs injectable) by providing analgesic/anesthetic/anti-inflammatory properties in one application.
- topical analgesic/anesthetic/anti-inflammatory has been used in human medicine (Friedman et al, 2001), mostly by dermatologists and dentists, but the present invention is a novel application for the swine industry.
- a preferred formulation of the invention is a gel comprising lidocaine (4%) and meloxicam (0.3%) gel (L/M gel) that could potentially be applied to the tail base and scrotum 30 minutes prior to tail docking and castration. This could be applied with a minimum of restraint (e.g. while the piglets are nursing, spray) and is therefore less painful and stressful to the animals.
- the properties of this formulation have shown release of M and L to be 98 and 95% respectively.
- the amount of applied product that is absorbed through the skin for M and L is 58 and 52% respectively. Therapeutic levels are obtained within 30 minutes for lidocaine (L) and one hour for meloxicam (M).
- Alternative formulations of the invention include but are not limited to: hydrogels, nanocrystalline formulations, dissolvable microneedles, non-dissolvable microneedles, incorporation into dermal patches or castration bands, no needle jet anesthesia technologies,
- Some embodiments of the invention also include livestock pharmaceutical products to address food producing animal's pain incurred during production procedures such as castration, tail docking, dehorning etc.
- the product may be supplied in 250 ml multiple dose dispensers (similar to a caulking compound) or sprayed using a spray dispenser. It is expected that the cost of treatment will be more than compensated for by improved performance, reduced medication costs and prevention of needles in meat products as has been shown in previous studies.
- Swine is used herein to refer to cloven-hoofed artiodactyls of the family Suidae. Typical examples include, but is not limited to hogs, pigs, and boars.
- Lidocam Topical Gel (4% lidocaine-0.3% meloxicam) is safe for piglets when provided at:
- Group 1 consisted of 3 animals (3 Males) receiving Lidocaine 4% Meloxicam 0.3 Topical Gel at the dose 0.5 mL to be applied to the base of the tail and 0.5 mL to be applied to the scrotal area, administered once.
- Group 2 consisted of 3 animals (3 Males) receiving Lidocaine 4% Meloxicam 0.3% Topical Gel at the dose 1 mL to be applied to the base of the tail and 1.0 mL to be applied to the Scrotal area, administered once.
- Group 3 consisted of 3 animals (3 Males) receiving Lidocaine 4% Meloxicam 0.3% Topical Gel at the dose 1.5 mL to be applied to the base of the tail and 1.5 mL to be applied to the Scrotal area, administered once.
- Group 4 consisted of 3 animals (3 Males) receiving Meloxicam 0.3% Topical Gel at the dose 1 mL to be applied to the base of the tail and 1.0 mL to be applied to the scrotal area, administered once.
- the Gel was applied to the 1) tail base and 2) scrotal area and dispersed over the application area. Coverage of product over intended surgical site is provided in Table 2. It was determined that 0.5 mL was insufficient to cover the intended area for provision of local anesthesia. The use of 1.0 mL provided appropriate coverage while 1.5 ml was excessive. The gel rapidly penetrated the skin as it was not observed after 10 minutes, 20 minutes and 30 minutes for the 0.5 mL, 1 mL and 1.5 mL dose respectively. After the gel had penetrated there was no evidence of residue or irritation at the application site.
- Group 1 consisted of 3 animals (3 Males) receiving Lidocaine 4% Meloxicam 0.1% Topical Gel at the dose 1 mL to be applied to the base of the tail and 1.0 mL to be applied to the scrotal area, administered once.
- Group 2 consisted of 3 animals (3 Males) receiving Lidocaine 4% Meloxicam 0.2% Topical Gel at the dose 1 mL to be applied to the base of the tail and 1.0 mL to be applied to the scrotal area, administered once.
- Group 3 consisted of 3 animals (3 Males) receiving Lidocaine 4% Meloxicam 0.3% Topical Gel at the dose 1 mL to be applied to the base of the tail and 1.0 mL to be applied to the scrotal area, administered once.
- Group 4 consisted of 3 animals (3 Males) receiving Meloxicam 5 mg/mL injected intramuscular at a dosage of 0.4 mg/kg (Metacam Injection).
- Topical applied Lidocaine/Meloxicam does not result in significant plasma levels of Meloxicam. His has been shown previously with Meloxicam in Dogs (4) and diclofenac epolamine in pigs (5). Plasma levels of intramuscular meloxicam (5 mg/mL) however were similar to those previously reported in pigs (6) (Table 2).
- Topical meloxicam rapidly penetrates the skin and subcutaneous tissues with peak concentrations at 2.7 to 3.7 hours. It is concentrated in these tissues and slowly released into the plasma where it is metabolized and released. With intramuscular injections of meloxicam the drug is rapidly distributed throughout all tissues and is then eliminated. There is a plasma and tissue dose response with topical meloxicam.
- the T 1/2 of Topical Lid 4% Mel 0.3% Gel Meloxicam is closest to that of injectable meloxicam.
- the peak dermal tissue concentration of Topical Lid 4% Mel 0.3% Gel Meloxicam is about 3 times that of injectable meloxicam. This is similar to that observed with Topical diclofenac and other NSAIDS which has been clinically proven to reduce pain and inflammation in humans (5, 7-12).
- Topical meloxicam is the concentration that will provide optimal tissues levels to control pain and inflammation in piglets following castration and tail docking.
- Lidocaine, meloxicam and gel samples were quantified by an in-house HPLC method.
- the mobile phase comprised methanol/acetate buffer pH 4.5 (45:55, V/V).
- the flow rate and injection volume used were 1.3 mL min-1 and 20 mL, respectively.
- the detection wavelength was set at 363 nm (meloxicam) and 230 nm (lidocaine). Under these conditions, the method was linear in the concentration range 0.2-100 mg mL-1; the LOD and LOQ values were 0.1 and 0.33 mg per mL, respectively.
- NMP was selected as the vehicle to formulate Lidocaine and Meloxicam gel.
- Lidocaine and Meloxicam was dissolved in varying amounts of NMP (8-15%, m/m).
- Carbopol Ultrez 10® was dispersed in water under continuous stirring using an overhead stirrer at 1000 rpm until it yielded a homogenous dispersion.
- Carbopol Ultrez 10® dispersion 0.5-1%, m/m
- Meloxicam gel formulations with different amounts of NMP and Carbopol Ultrez 10® were formulated.
- Formulation F4 (Table I) was selected for further studies based on its transparency, composition and viscosity.
- Composition (%, wt/wt) Ingredient
- F1 F2 F3 F4 F5 Meloxicam 0.3 0.3 0.3 0.3 0.3 0.3 Lidocaine (base) 4 4 4 4 4 N-methyl pyrrolidone 8 8 8 10 15 (NMP) Carbopol Ultrez-10 0.5 0.75 1.00 0.75 0.75 Triethanolamine 1.5 1.75 2.0 1.0 0.5 Water (q.s.) 100 100 100 100 100 100 100
- Lidocaine-Meloxicam gel was weighed in a 100-mL volumetric flask, dissolved in methanol and diluted suitably prior to HPLC analysis. Viscosity of Meloxicam gel was determined using a Brookfield synchrolectric viscometer, model RVT (Brookfield Engineering Laboratories, Inc., USA). To determine the spreadability of Lidocaine-Meloxicam gel, 0.5 g of gel was placed within a circle of 1 cm diameter premarked on a glass plate, over which a second glass plate was placed. A weight of 500 g was allowed to rest on the upper glass plate for 5 min. The increase in the diameter due to gel spreading was noted. The pH of the 10% (m/m) gel was determined using a digital pH meter.
- Physicochemical stability of Lidocaine-Meloxicam gel was studied by subjecting samples to accelerated stability conditions at 25° C./60% RH, 30° C./60% RH and 40° C./75% RH as per ICH guidelines for a period of 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 18 months and 24 months.
- formulations F4 and F5 were transparent in appearance compared to F1, F2 and F3 (Table I).
- Concentration of Carbopol Ultrez-10® was optimized on the basis of the desired viscosity and spreadability.
- Carbopol Ultrez-10® at a concentration of 0.5%, m/m produced a gel of fluid consistency, whereas a gel of high viscosity and lower spreadability was obtained at 1%, m/m, concentration.
- Optimum viscosity and spreadability were obtained at Carbopol Ultrez-10® concentration of 0.75%, m/m.
- Formulations F4 and F5 were transparent in appearance and had the desired viscosity; however, F4 was selected for further studies because of its lower concentration of NMP.
- Viscosity of Meloxicam gel was found to be 7.9 ⁇ 10 6 mPas.
- Lidocaine-Meloxicam gel subjected to accelerated stability conditions exhibited acceptable stability with respect to drug concentration.
- the Lidocaine and Meloxicam assay values for the samples stored at 25° C./60% RH were found to range between 100.0 and 99.4% after 1, 2, 3, 6, 12, 18 and 24 months of storage and compared to the initial value of 100.3% the observed differences in assay values were not statistically significant.
- the assay values for Lidocaine and meloxicam samples stored at 40° C./75% RH were between 95 and 100% after 1, 2, 3 and 6 months.
- Sample processing Samples were subjected to in vitro analysis for quantification of meloxicam by a validated procedure using a high performance liquid chromatography system (HPLC) according to a previously reported validated procedure.
- HPLC high performance liquid chromatography system
- Topical applied Lidocaine/Meloxicam does not result in significant plasma levels of Meloxicam. This has been shown previously with Meloxicam in Dogs (15) and diclofenac epolamine in pigs (16). Plasma levels of intramuscular meloxicam (5 mg/mL) however were similar to those previously reported in pigs (17) (Table 1) Pharmacokinetic parameters are compared between the treatment groups in Tables 1.
- Topical meloxicam rapidly penetrates the skin and subcutaneous tissues with peak concentrations at 2.7 to 3.7 hours. It is concentrated in these tissues and slowly released into the plasma where it is metabolized and released. With intramuscular injections of meloxicam the drug is rapidly distributed throughout all tissues and is then eliminated. There is a plasma and tissue dose response with topical meloxicam.
- the T 1/2 of Topical Lid 4% Mel 0.3% Gel Meloxicam is closest to that of injectable meloxicam.
- the peak dermal tissue concentration of Topical Lid 4% Mel 0.3% Gel Meloxicam is about 3 times that of injectable meloxicam. This is similar to that observed with Topical diclofenac and other NSAIDS which has been clinically proven to reduce pain and inflammation in humans.
- Topical meloxicam is the concentration that will provide optimal tissues levels to control pain and inflammation in piglets following castration and tail docking.
- Lidocaine Gel has an extensive history of use in humans (21-23). It has been shown that Lidocaine base is ideal for local anesthesia of the skin (21-23) as hydrophobic molecules readily cross the intact skin barrier. 1.0 mL is the ideal volume for delivery at the scrotum and the tail base. The topical gel did not cause irritation to the skin and was rapidly absorbed into the dermis.
- Tail Base In this study the onset of local anesthesia to the skin was provided at time 40 minutes for piglets receiving 0.5 mL of Lidocaine 4% Meloxicam 0.3% Topical Gel and local anesthesia effect was provided for 56.7 minutes. Piglets receiving 1 mL and 1.5 mL of Lidocaine 4% Meloxicam 0.3% Topical Gel had an onset time of local dermal of anesthesia of 30 minutes and a duration of 86.7 to 90 minutes.
- This research establishes a volume of 1 mL on the scrotum and tail base and a time for castration and tail docking between 30 and 90 minutes.
- Topical Lidocaine toxicity has had remarkable few reports of adverse events. To date systemic toxicity have been reported in humans receiving topical local anesthetics. These have been reported with the use of excessive product over large dermal areas (24).
- lidocaine toxicity causes a decrease in QT interval but no change in PT and heart rate (25).
- Newborn piglet receiving intravenous lidocaine did not have any cardiovascular effects but seizures were induced with high dosages (26).
- Lidocam Topical Gel (4% lidocaine-0.3% meloxicam) is safe for piglets when provided at
- Control 1 mL Control gel (no active) on tail+1 mL Control gel (no active) on scrotum or rump area.
- Electrocutaneous Stimulation Prior to Castration electrocutaneous stimulation of the surgical site was performed and the reaction scored. Electrocutaneous stimulation was also performed at the surgical site at times 3 hours and 24 hours after castration. This measured the short term and long term effects of Lidocam.
- Electrocutaneous Stimulation 30 min 1.83 ⁇ 0.15 0.23 ⁇ 0.08 ⁇ 0.0001 (Score) 3 hr 1.61 ⁇ 0.17 0.17 ⁇ 0.07 ⁇ 0.0001 24 hr 1.61 ⁇ 0.16 0.44 ⁇ 0.11 ⁇ 0.0001 Electrocutaneous Stimulation 30 min 2 23 ⁇ 0.0001 (Number No Reaction to Stimulus) 3 hr 2 23 ⁇ 0.0001 24 hr 4 17 ⁇ 0.0001 Stress Maximum 30 min 11.10 ⁇ 2.94 5.67 ⁇ 1.51 0.0104 Vocalization Mean 30 min 0.065 ⁇ 0.01 0.031 ⁇ 0.008 0.0104 Duration 30 min 1.17 ⁇ 0.30 0.57 ⁇ 0.15 0.0104 Body Weight (Kg) Day 0 2.33 ⁇ 0.07 2.25 ⁇ 0.07 0.8778 Day 6 3.22 ⁇ 0.13 3.43 ⁇ 0.15 0.0705 Day 13 4.44 ⁇ 0.15 4.
- Lidocam acted to reduce pain at the time of the castration procedure (reduced reaction to electrocutaneous stimulation and stress vocalization). Plasma cortisol and substance P were not significantly reduced but there was a trend for reduced levels in Lidocam treated animals. Behaviors were not different but due to multiple data collections they could only be observed for 30 minutes. Lidocam resulted in increased body weights at 2 weeks following castration. Lidocam did not impair would healing.
- Lidocam acted to reduce pain at the time of the tail docking procedure (reduced reaction to electrocutaneous stimulation and stress vocalization). Plasma cortisol and substance P were not significantly reduced but there was a trend for reduced levels in Lidocam treated animals. Behaviors were not different but due to multiple data collections they could only be observed for 30 minutes. Lidocam resulted in increased body weights at 2 weeks following tail docking. Lidocam did not impair would healing.
- Lidocam acted to reduce pain at the time of the castration and tail docking procedure (reduced reaction to electrocutaneous stimulation and stress vocalization). Plasma cortisol and substance P were significantly reduced. Behaviors were not different but due to multiple data collections they could only be observed for 30 minutes. Lidocam resulted in increased body weights at 2 weeks following tail docking. Lidocam did not impair would healing.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
- This invention relates to topical compositions and methods for treating animals in pain. This invention also relates to methods of treating pain associated with castration and tail docking.
- Castration and tail docking of piglets is a common management practice on commercial swine farms to prevent the occurrence of boar taint, aggressive behaviours and infections associated with tail chewing. These procedures can cause acute pain-induced stress which is an animal welfare concern, negative public perception concerning these procedures being performed without analgesia or anesthesia is growing.
- In Canada and in most developed countries piglets undergo certain elective surgical procedures. Castration is performed to eliminate boar taint and improve the quality of meat. Tail docking is performed to reduce tail chewing which leads to infections, abscesses, morbidity and mortalities as well as condemnation of animals and meat. In Canada, approximately 15 million piglets undergo castration and 30 million tail docking.
- It has well established that both castration and tail docking are both painful, yet the use of anesthetics and analgesics have not been used in Canada as of Jul. 2016. As of Jul. 2016, Canada the Codes of Practice require the use of anesthetics for castration procedure and post-operative analgesia of piglets of all ages. The use of anesthetics and analgesics are currently not required for tail docking but this is expected in future Codes of Practice Documents. There are currently no products that are suitable to meet the requirements of the pork industry for short and long term pain control.
- Research by Hansson et al. (2011) evaluated the effect of local anesthesia and/or analgesia on pain responses induced by piglet castration. The results are shown in Example 1.
- Based on the above study it has been established that lidocaine and meloxicam are effective in the pig model for both short and long term pain associated with castration, however the excessive handling required to administer two injections and the injections in themselves create a level of stress and pain for the animals. The excessive handling required to administer two injections and the injections in themselves create a level of stress and pain for the animals. Lidocaine is very acidic and causes significant pain when injected.
- Notwithstanding the usefulness of the above-described methods, a need still exists for a topical formulation for the treatment of pain.
- Meloxicam is a newer NSAID in the oxicam group that has preferential (but not specific) binding to cyclo-oxygenase-2 receptors. It has been approved for use in piglets in several European countries including the United Kingdom as a single IV or SC dose of 0.4 mg/kg. Lidocaine is a common local anesthetic and class-1b antiarrhythmic drug. Lidocaine is used topically to relieve itching, burning, and pain from skin inflammations, injected as a dental anesthetic, or used as a local anesthetic for minor surgery. Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.
- Topical lidocaine (L) and non-steroidal anti-inflammatory drugs (NSAIDs) such as meloxicam exist individually as commercial products and have been shown to be effective in humans, lambs and piglets for long term pain. No topical combination exists that addresses both short and long term pain. No such registered products exist for the treatment of short and long term pain associated with procedures performed on animals for food production.
- National Farm Animal Care Council. 2014. Code of practice for the care and handling of pigs.
- Hansson, M., Lundeheim, N., Nyman, G. and G. Johansson. 2011. Effect of local anaesthesia and/or analgesia on pain responses induced by piglet castration. Acta Veterinaria Scandinavica. 53: 34.
- Friedman, P. M., Mafong, E. A., Friedman, E. S. and R. G. Geronemus. 2001. Topical anesthetics update: EMLA and beyond. Dermatol. Surg. 27:12 December.
- This invention provides a topical analgesic/anesthetic/anti-inflammatory product to control both short and long term pain in animals.
- Therefore, it would be beneficial to the welfare of the pig and the swine industry to develop an efficacious, topical, commercially available product that addresses the physiological and behavioral response to the acute pain associated with castration/tail docking which currently no registered product exists for pigs. The present invention is a topical analgesic/anesthetic/anti-inflammatory product to control both short and long term pain.
- Lidocam (4% lidocaine and 0.3% Meloxicam) was developed to address the animal welfare and production requirements by the Canadian swine industry. Lidocam is a topical gel containing 4% lidocaine base and 0.3% meloxicam that are able to rapidly penetrate into the skin and provide both short term local anesthesia and longer term control of pain and inflammation. This product is intended to address castration and tail docking in piglets. It also has other applications for the pork industry (e.g. Crate sores) and other food animal production.
- The product was shown to be effective in controlling pain and inflammation in piglets undergoing castration and tail docking. The use of the product had production economic benefits as piglets treated with the product had increased growth rates compared to untreated controls. The product was easy to administer and was shown to be safe to piglets even at 9 times the required dose. Tissue residue studies were conducted and it was shown that the active agents were eliminated from the meat and organs within 2 weeks.
- A topical lidocaine/meloxicam will provide to the industry a simple, inexpensive and effective solution to meet the Code of Practice for the Care and Handling of Pigs. There will be no need to inject animals whereby reducing animal stress and avoid needle stick injuries to staff.
- The compositions and methods of the present invention show the ability to produce a topical gel for use in piglets that would be effective, safe, stable and could be sprayed onto the surgical site.
- Some embodiments of the invention also include livestock pharmaceutical products to address food producing animal's pain incurred during production procedures such as castration, tail docking, dehorning etc.
- The properties of this formulation have shown release of M and L to be 98 and 95% respectively. The amount of applied product that is absorbed through the skin for M and L is 58 and 52% respectively. Therapeutic levels are obtained within 30 minutes for L and one hour for M. Topical L and non-steroidal anti-inflammatory drugs (NSAIDs) such as M exist individually as commercial products and have been shown to be effective in humans, lambs and piglets but a combination would address short and long term pain.
- The devices and methods of the present invention alleviate the above-described problems and, in addition, provide pain mitigation from other procedures including but not limited to: wound care, wound management, foot rot, dental procedures, cyst removal, de-horning, de-clawing, de-horning, de-beaking, beak trimming (including Infra-red procedures), branding, implantation of RFID or ear-tags, tattooing, microchipping, cannibalism, self-mutilation, grooming, reduced antibiotic treatments; increased growth rates; and reduced mortalities.
- With the following enabling description of the drawings, the apparatus should become evident to a person of ordinary skill in the art.
- Not applicable.
- The present invention involves a method of treating an animal for pain comprising administering a topical composition comprising an effective dose of a local anesthetic and an analgesic. In preferred embodiments of the invention, the animal being treated is swine, more preferably pigs or piglets.
- The present invention also is a composition for the topical treatment of an animal comprising about 0.1% to about 1% meloxicam, preferably about 0.2% to about 0.4% meloxicam; and about 2% to about 7% lidocaine, preferably about 3% to about 5% lidocaine.
- Embodiments of the invention provide a new tool that will allow reduced pain and stress in castration and tail docking procedures, in a non-invasive manner (topical vs injectable) by providing analgesic/anesthetic/anti-inflammatory properties in one application. The concept of topical analgesic/anesthetic/anti-inflammatory has been used in human medicine (Friedman et al, 2001), mostly by dermatologists and dentists, but the present invention is a novel application for the swine industry.
- A preferred formulation of the invention is a gel comprising lidocaine (4%) and meloxicam (0.3%) gel (L/M gel) that could potentially be applied to the tail base and scrotum 30 minutes prior to tail docking and castration. This could be applied with a minimum of restraint (e.g. while the piglets are nursing, spray) and is therefore less painful and stressful to the animals. The properties of this formulation have shown release of M and L to be 98 and 95% respectively. The amount of applied product that is absorbed through the skin for M and L is 58 and 52% respectively. Therapeutic levels are obtained within 30 minutes for lidocaine (L) and one hour for meloxicam (M).
- Alternative formulations of the invention include but are not limited to: hydrogels, nanocrystalline formulations, dissolvable microneedles, non-dissolvable microneedles, incorporation into dermal patches or castration bands, no needle jet anesthesia technologies,
- Some embodiments of the invention also include livestock pharmaceutical products to address food producing animal's pain incurred during production procedures such as castration, tail docking, dehorning etc.
- It is expected the withdrawal time will be less than 7 days. The product may be supplied in 250 ml multiple dose dispensers (similar to a caulking compound) or sprayed using a spray dispenser. It is expected that the cost of treatment will be more than compensated for by improved performance, reduced medication costs and prevention of needles in meat products as has been shown in previous studies.
- One skilled in the art will recognize that the invention as described here may be reconfigured into different combinations, elements, and processes which are included within the scope of the invention.
- The following definitions are used in reference to the invention:
- (A) Swine is used herein to refer to cloven-hoofed artiodactyls of the family Suidae. Typical examples include, but is not limited to hogs, pigs, and boars.
- Research by Hansson et al. (2011) evaluated the effect of local anesthesia and/or analgesia on pain responses induced by piglet castration. Four male piglets in each of 141 litters in five herds were randomly allocated to one of four treatments: castration with no analgesic/anesthetic (C, controls), analgesia (M, meloxicam), local anesthesia (L, lidocaine) or local anesthesia and analgesia (L+M, lidocaine and meloxicam). Lidocaine (L, LM) was injected at least three minutes prior to castration and meloxicam (M, LM) was injected after castration. They demonstrated that piglets castrated with lidocaine produced calls with lower intensity (p<0.001) and less resistance movements (p<0.001) during castration. Piglets that were given meloxicam had less pain related behaviour on both the castration day (p=0.06, ns) and the following day (p=0.02). The proportion of piglets with high serum amyloid A (an acute phase protein that increases with stress, trauma, infection or inflammation) (over threshold values 200, 400 mg/l) was higher (p=0.005; p=0.05) for C +L compared to M+LM. Ear temperature was high (p<0.01) for controls compared to L and LM. The study concluded that lidocaine reduced pain during castration and that meloxicam reduced pain after castration.
-
-
% g per Ingredients in w/w mg/mL Ingredients in 5 kg Meloxicam 0.3% 3 Meloxicam 15.0 Lidocaine Base 4% 40 Lidocaine Base 200 Carbopol Ultrez -10 0.75% 7.5 Carbopol Ultrez -10 37.5 Triethanolamine 1% 10 Triethanolamine 50 N-methyl 10% 100 N-methyl pyrrolidone 500 pyrrolidone (NMP) Brilliant Blue FCF 0.05% 0.5 Brilliant Blue FCF 2.5 Water 83.9% 839 Water 4195 - Lidocam Topical Gel (4% lidocaine-0.3% meloxicam) is safe for piglets when provided at:
- A. 1X=1 mL Lidocam gel on tail+1 mL Lidocam gel on scrotum or rump area;
- B. 2X=2 mL Lidocam gel on tail+2 mL Lidocam gel on scrotum or rump area;
- C. 3X=3 mL Lidocam gel on tail+3 mL Lidocam gel on scrotum or rump area;
- D. 1X OT=1 mL Lidocam gel on tail+1 mL Lidocam gel on scrotum or rump area and 2 mL oral Lidocam;
- E. Control=1 mL Control gel (no active) on tail+1 mL Control gel (no active) on scrotum or rump area.
- This is based upon the clinical observation, weight changes, electrocardiographic recordings, clinical pathology, gross pathology and histopathology.
-
-
- a) To determine duration of skin penetration of different volumes of 4% Lidocaine and 0.3% Meloxicam Topical Gel.
- b) To determine the time to Onset of loss of Dermal sensation of 4% Lidocaine and 0.3% Meloxicam Topical Gel
- c) To determine the volume of 4% Lidocaine and 0.3% Meloxicam Topical Gel to be applied to the tail base and scrotal area.
- Group 1 consisted of 3 animals (3 Males) receiving Lidocaine 4% Meloxicam 0.3 Topical Gel at the dose 0.5 mL to be applied to the base of the tail and 0.5 mL to be applied to the scrotal area, administered once. Group 2 consisted of 3 animals (3 Males) receiving Lidocaine 4% Meloxicam 0.3% Topical Gel at the dose 1 mL to be applied to the base of the tail and 1.0 mL to be applied to the Scrotal area, administered once. Group 3 consisted of 3 animals (3 Males) receiving Lidocaine 4% Meloxicam 0.3% Topical Gel at the dose 1.5 mL to be applied to the base of the tail and 1.5 mL to be applied to the Scrotal area, administered once. Group 4 consisted of 3 animals (3 Males) receiving Meloxicam 0.3% Topical Gel at the dose 1 mL to be applied to the base of the tail and 1.0 mL to be applied to the scrotal area, administered once.
- The Gel was applied to the 1) tail base and 2) scrotal area and dispersed over the application area. Coverage of product over intended surgical site is provided in Table 2. It was determined that 0.5 mL was insufficient to cover the intended area for provision of local anesthesia. The use of 1.0 mL provided appropriate coverage while 1.5 ml was excessive. The gel rapidly penetrated the skin as it was not observed after 10 minutes, 20 minutes and 30 minutes for the 0.5 mL, 1 mL and 1.5 mL dose respectively. After the gel had penetrated there was no evidence of residue or irritation at the application site.
-
Onset Duration of of Treatment Anesthesia Anesthesia Scrotum Group 1 0.5 mL Lidocaine 4% Meloxicam 0.3% 36.7 53.3 Topical Gel Group 2 1.0 mL Lidocaine 4% Meloxicam 0.3% 30 90 Topical Gel Group 3 1.5 mL Lidocaine 4% Meloxicam 0.3% 30 90 Topical Gel Group 4 1.0 mL Meloxicam 0.3% Topical Gel No Effect No Effect Tail Base Group 1 0.5 mL Lidocaine 4% Meloxicam 0.3% 40 56.7 Topical Gel Group 2 1.0 mL Lidocaine 4% Meloxicam 0.3% 30 86.7 Topical Gel Group 3 1.5 mL Lidocaine 4% Meloxicam 0.3% 30 90 Topical Gel Group 4 1.0 mL Meloxicam 0.3% Topical Gel No Effect No Effect - Objective: 1) to determine the ideal meloxicam concentration and volume of gel to be applied to the scrotum and tail of piglets undergoing castration/tail docking. 2) To compare blood and tissue meloxicam levels of piglets receiving topical meloxicam to piglets receiving intramuscular meloxicam.
- Group 1 consisted of 3 animals (3 Males) receiving Lidocaine 4% Meloxicam 0.1% Topical Gel at the dose 1 mL to be applied to the base of the tail and 1.0 mL to be applied to the scrotal area, administered once. Group 2 consisted of 3 animals (3 Males) receiving Lidocaine 4% Meloxicam 0.2% Topical Gel at the dose 1 mL to be applied to the base of the tail and 1.0 mL to be applied to the scrotal area, administered once. Group 3 consisted of 3 animals (3 Males) receiving Lidocaine 4% Meloxicam 0.3% Topical Gel at the dose 1 mL to be applied to the base of the tail and 1.0 mL to be applied to the scrotal area, administered once. Group 4 consisted of 3 animals (3 Males) receiving Meloxicam 5 mg/mL injected intramuscular at a dosage of 0.4 mg/kg (Metacam Injection).
- Topical applied Lidocaine/Meloxicam does not result in significant plasma levels of Meloxicam. His has been shown previously with Meloxicam in Dogs (4) and diclofenac epolamine in pigs (5). Plasma levels of intramuscular meloxicam (5 mg/mL) however were similar to those previously reported in pigs (6) (Table 2).
- Pharmacokinetic parameters are compared between the treatment groups in Tables 6.
- Topical meloxicam rapidly penetrates the skin and subcutaneous tissues with peak concentrations at 2.7 to 3.7 hours. It is concentrated in these tissues and slowly released into the plasma where it is metabolized and released. With intramuscular injections of meloxicam the drug is rapidly distributed throughout all tissues and is then eliminated. There is a plasma and tissue dose response with topical meloxicam. The T1/2 of Topical Lid 4% Mel 0.3% Gel Meloxicam is closest to that of injectable meloxicam. The peak dermal tissue concentration of Topical Lid 4% Mel 0.3% Gel Meloxicam is about 3 times that of injectable meloxicam. This is similar to that observed with Topical diclofenac and other NSAIDS which has been clinically proven to reduce pain and inflammation in humans (5, 7-12).
- Based upon human topical NSAID products, it is desirable have a high local NSAID concentration and low systemic concentrations. In this way there is less potential adverse events associated with gastric, liver and kidney damage (11, 12). Safety studies in piglets need to be performed to confirm the safety of topical meloxicam in piglets. Based upon the half-life and levels in tissue, is concluded that 0.3% Topical meloxicam is the concentration that will provide optimal tissues levels to control pain and inflammation in piglets following castration and tail docking.
- Lidocaine, meloxicam and gel samples (solubility and stability studies) were quantified by an in-house HPLC method. The mobile phase comprised methanol/acetate buffer pH 4.5 (45:55, V/V). The flow rate and injection volume used were 1.3 mL min-1 and 20 mL, respectively. The detection wavelength was set at 363 nm (meloxicam) and 230 nm (lidocaine). Under these conditions, the method was linear in the concentration range 0.2-100 mg mL-1; the LOD and LOQ values were 0.1 and 0.33 mg per mL, respectively.
- NMP was selected as the vehicle to formulate Lidocaine and Meloxicam gel. To formulate 4% Lidocaine-0.3% Meloxicam 0.3% gel, Lidocaine and Meloxicam was dissolved in varying amounts of NMP (8-15%, m/m). Carbopol Ultrez 10® was dispersed in water under continuous stirring using an overhead stirrer at 1000 rpm until it yielded a homogenous dispersion. To the Lidocaine-Meloxicam solution, Carbopol Ultrez 10® dispersion (0.5-1%, m/m) was added under continuous stirring to yield a homogenous dispersion, which in turn was neutralized with triethanolamine to obtain a transparent gel. Meloxicam gel formulations with different amounts of NMP and Carbopol Ultrez 10® were formulated. Formulation F4 (Table I) was selected for further studies based on its transparency, composition and viscosity.
-
Composition (%, wt/wt) Ingredient F1 F2 F3 F4 F5 Meloxicam 0.3 0.3 0.3 0.3 0.3 Lidocaine (base) 4 4 4 4 4 N-methyl pyrrolidone 8 8 8 10 15 (NMP) Carbopol Ultrez-10 0.5 0.75 1.00 0.75 0.75 Triethanolamine 1.5 1.75 2.0 1.0 0.5 Water (q.s.) 100 100 100 100 100 - To determine the drug content, approximately 1 g of Lidocaine-Meloxicam gel was weighed in a 100-mL volumetric flask, dissolved in methanol and diluted suitably prior to HPLC analysis. Viscosity of Meloxicam gel was determined using a Brookfield synchrolectric viscometer, model RVT (Brookfield Engineering Laboratories, Inc., USA). To determine the spreadability of Lidocaine-Meloxicam gel, 0.5 g of gel was placed within a circle of 1 cm diameter premarked on a glass plate, over which a second glass plate was placed. A weight of 500 g was allowed to rest on the upper glass plate for 5 min. The increase in the diameter due to gel spreading was noted. The pH of the 10% (m/m) gel was determined using a digital pH meter.
- Physicochemical stability of Lidocaine-Meloxicam gel was studied by subjecting samples to accelerated stability conditions at 25° C./60% RH, 30° C./60% RH and 40° C./75% RH as per ICH guidelines for a period of 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 18 months and 24 months. The stability samples (n=3) were analyzed for drug content, pH, viscosity, release and spreadability.
- Due to higher concentration of NMP, formulations F4 and F5 were transparent in appearance compared to F1, F2 and F3 (Table I). Concentration of Carbopol Ultrez-10® was optimized on the basis of the desired viscosity and spreadability. Carbopol Ultrez-10® at a concentration of 0.5%, m/m produced a gel of fluid consistency, whereas a gel of high viscosity and lower spreadability was obtained at 1%, m/m, concentration. Optimum viscosity and spreadability were obtained at Carbopol Ultrez-10® concentration of 0.75%, m/m. Formulations F4 and F5 were transparent in appearance and had the desired viscosity; however, F4 was selected for further studies because of its lower concentration of NMP. Lidocaine-Meloxicam content of the F4 gel was found to be 100.0±1.5% (n=3) of the theoretical value (1%, m/m)). Viscosity of Meloxicam gel was found to be 7.9×106 mPas. The pH value of Meloxicam gel was 7.6±0.1 (n=3), which is a physiologically acceptable pH and in principle devoid of any skin irritation. Spreadability of the topically applied formulation is an important property considering patient compliance. Formulations with higher spreadability values allow ease of application and thereby increased surface area available for drug permeation. The increase in Meloxicam gel diameter following the spreadability test was found to be 7.8 cm (n=3), which is indicative of good spreadability.
- Lidocaine-Meloxicam gel subjected to accelerated stability conditions exhibited acceptable stability with respect to drug concentration. The Lidocaine and Meloxicam assay values for the samples stored at 25° C./60% RH were found to range between 100.0 and 99.4% after 1, 2, 3, 6, 12, 18 and 24 months of storage and compared to the initial value of 100.3% the observed differences in assay values were not statistically significant. The assay values for Lidocaine and meloxicam samples stored at 40° C./75% RH were between 95 and 100% after 1, 2, 3 and 6 months.
- The results present a physicochemically stable and non irritant topical gel of Lidocaine-Meloxicam that could deliver a significant amount of Meloxicam across the skin.
-
- STUDY OBJECTIVES: 1) To determine the ideal meloxicam concentration and volume of gel to be applied to the scrotum and tail of piglets undergoing castration/tail docking. 2) To compare blood and tissue meloxicam levels of piglets receiving topical meloxicam to piglets receiving intramuscular meloxicam.
- Treatment: Group 1 consisted of 3 animals (3 Males) receiving Lidocaine 4% Meloxicam 0.1% Topical Gel at the dose 1 mL to be applied to the base of the tail and 1.0 mL to be applied to the scrotal area. Group 2 consisted of 3 animals (3 Males) receiving Lidocaine 4% Meloxicam 0.2% Topical Gel at the dose 1 mL to be applied to the base of the tail and 1.0 mL to be applied to the scrotal area. Group 3 consisted of 3 animals (3 Males) receiving Lidocaine 4% Meloxicam 0.3% Topical Gel at the dose 1 mL to be applied to the base of the tail and 1.0 mL to be applied to the scrotal area. Group 4 will consist of 3 animals (3 Males) receiving Meloxicam 5 mg/mL injected intramuscular at a dosage of 0.4 mg/kg (Metacam Injection)
- Sample Collection: Blood: Blood was collected by anterior vena cava venipuncture. Blood was collected at the following times: 0, 0.5 hr, 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr and 24 hr. Tissue: The skin and subcutaneous tissue was collected from the scrotal area where the gel was applied using as 3 mm disposable biopsy punch (Dormer). Tissue: 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr and 24 hr.
- Sample processing: Samples were subjected to in vitro analysis for quantification of meloxicam by a validated procedure using a high performance liquid chromatography system (HPLC) according to a previously reported validated procedure. An Agilent 1200 HPLC (Mississauga, Ontario) equipped with a quaternary pump, an auto sampler, UV detector and Chem Station software was used for all analysis. Teloxicam was used as an internal standard.
- Results: Pharmacokinetics/Pharmacodynamics of Topical Lidocam in Piglets
- Topical applied Lidocaine/Meloxicam does not result in significant plasma levels of Meloxicam. This has been shown previously with Meloxicam in Dogs (15) and diclofenac epolamine in pigs (16). Plasma levels of intramuscular meloxicam (5 mg/mL) however were similar to those previously reported in pigs (17) (Table 1) Pharmacokinetic parameters are compared between the treatment groups in Tables 1.
- Topical meloxicam rapidly penetrates the skin and subcutaneous tissues with peak concentrations at 2.7 to 3.7 hours. It is concentrated in these tissues and slowly released into the plasma where it is metabolized and released. With intramuscular injections of meloxicam the drug is rapidly distributed throughout all tissues and is then eliminated. There is a plasma and tissue dose response with topical meloxicam. The T1/2 of Topical Lid 4% Mel 0.3% Gel Meloxicam is closest to that of injectable meloxicam. The peak dermal tissue concentration of Topical Lid 4% Mel 0.3% Gel Meloxicam is about 3 times that of injectable meloxicam. This is similar to that observed with Topical diclofenac and other NSAIDS which has been clinically proven to reduce pain and inflammation in humans.
- Based upon human topical NSAID products, it is desirable have a high local NSAID concentration and low systemic concentrations. In this way there is less potential adverse events associated with gastric, liver and kidney damage. Based upon the half-life and levels in tissue, it is concluded that 0.3% Topical meloxicam is the concentration that will provide optimal tissues levels to control pain and inflammation in piglets following castration and tail docking.
-
TABLE 1 Comparative Summary of Pharmacokinetic Parameters Plasma Pharmacokinetics Topical Lid 4% Mel 0.3% Gel Topical Lid Topical Lid Meloxicam 4% Mel 4% Mel IM (% of IM 0.2% Gel 0.1% Gel Meloxicam Meloxicam) Meloxicam Meloxicam Group 4 Group 3 Group 2 Group 1 Cmax 1633 62.7 22.9 12.1 (ug/mL) Tmax (hrs) 2 2.3 2.3 3.3 AUCt 11243 442.7 205.7 119.0 (ng-hr/mL) AUCi 11496 677.7 223.0 119.0 (ng-hr/mL) T1/2 (hr) 5.0 17.4 5.7 2.5 Tissue Pharmacokinetics Topical Lid Topical Lid Topical Lid 4% Mel 4% Mel 4% Mel IM 0.3% Gel 0.2% Gel 0.1% Gel Meloxicam Meloxicam Meloxicam Meloxicam Group 4 Group 3 Group 2 Group 1 Cmax (ug/g) 980 2900 1081 507 Tmax (hrs) 2 2.7 2.7 3.7 AUCt 6933 26080 10621 4655 (ng-hr/g) AUCi 6995 26568 10707 4667 (ng-hr/g) T1/2 (hr) 4.0 3.6 2.9 2.2 -
- Objectives: 1) To determine duration of skin penetration of different volumes of Lidocam (4% Lidocaine and 0.3% Meloxicam) Topical Gel. 2) To determine the time to Onset of loss of Dermal sensation of Lidocam (4% Lidocaine and 0.3% Meloxicam) Topical Gel. 3) To determine the volume of Lidocam (4% Lidocaine and 0.3% Meloxicam) Topical Gel to be applied to the tail base and scrotal area.
- Treatment: Group 1 consisted of 3 animals (3 Males) receiving Lidocam Topical Gel at the dose 0.5 mL to be applied to the base of the tail and 0.5 mL to be applied to the scrotal area, administered once. Group 2 consisted of 3 animals (3 Males) receiving Lidocam Topical Gel at the dose 1 mL to be applied to the base of the tail and 1.0 mL to be applied to the scrotal area, administered once. Group 3 consisted of 3 animals (3 Males) receiving Lidocam Topical Gel at the dose 1.5 mL to be applied to the base of the tail and 1.5 mL to be applied to the scrotal area, administered once. Group 4 consisted of 3 animals (3 Males) receiving Meloxicam 0.3% Topical Gel at the dose 1 mL to be applied to the base of the tail and 1.0 mL to be applied to the scrotal area, administered once.
- Response to Cutaneous Stimulation: Cutaneous stimulation was performed according to the procedure of Fierheller et al (13). A peripheral variable output nerve stimulator (Sun Medical Microstimulator) and infant monitoring electrode was used to stimulate the skin over the incisional area of the piglet's tail or scrotal area. The uniformly effective stimulus was established to be setting 90 mAmp. Briefly, the piglets were placed on an examination table and loosely restrained by hand. After the piglet had become relaxed the electrode probe was placed against the test area. Animals were stimulated with a burst of 4×90mAmp stimuli. The monitor to the stimulus noted a positive response to the stimulus included vocalization (squeal), body movement and tail movement or a negative response.
- For each piglet electrocutaneous stimulation was performed every 10 minutes from time 0 to time 120 minutes.
- Dermal Observation: The tail base and scrotal area were observed every 2 hours. The degree of irritation was recorded.
- Determination of Onset, Duration and Efficacy of 4% Lidocaine and 0.3% Meloxicam Topical Gel in Piglets. The summary of Onset and duration of local anesthesia is provided in Table 2 (below).
-
TABLE 2 Summary Cutaneous Electrostimulation of tail base and scrotum Onset Duration of of Treatment Anesthesia Anesthesia Scrotum Group 1 0.5 mL Lidocaine 4% Meloxicam 0.3% 36.7 53.3 Topical Gel Group 2 1.0 mL Lidocaine 4% Meloxicam 0.3% 30 90 Topical Gel Group 3 1.5 mL Lidocaine 4% Meloxicam 0.3% 30 90 Topical Gel Group 4 1.0 mL Meloxicam 0.3% Topical Gel No Effect No Effect Tail Base Group 1 0.5 mL Lidocaine 4% Meloxicam 0.3% 40 56.7 Topical Gel Group 2 1.0 mL Lidocaine 4% Meloxicam 0.3% 30 86.7 Topical Gel Group 3 1.5 mL Lidocaine 4% Meloxicam 0.3% 30 90 Topical Gel Group 4 1.0 mL Meloxicam 0.3% Topical Gel No Effect No Effect - Lidocaine Gel has an extensive history of use in humans (21-23). It has been shown that Lidocaine base is ideal for local anesthesia of the skin (21-23) as hydrophobic molecules readily cross the intact skin barrier. 1.0 mL is the ideal volume for delivery at the scrotum and the tail base. The topical gel did not cause irritation to the skin and was rapidly absorbed into the dermis.
- Scrotum: In this study the onset of local anesthesia to the skin was provided at time 36.7 minutes for piglets receiving 0.5 mL of Lidocaine 4% Meloxicam 0.3% Topical Gel and local anesthesia effect was provided for 53.3 minutes. Piglets receiving 1 mL and 1.5 mL of Lidocaine 4% Meloxicam 0.3% Topical Gel had an onset time of local dermal of anesthesia of 30 minutes and a duration of 90 minutes.
- Tail Base: In this study the onset of local anesthesia to the skin was provided at time 40 minutes for piglets receiving 0.5 mL of Lidocaine 4% Meloxicam 0.3% Topical Gel and local anesthesia effect was provided for 56.7 minutes. Piglets receiving 1 mL and 1.5 mL of Lidocaine 4% Meloxicam 0.3% Topical Gel had an onset time of local dermal of anesthesia of 30 minutes and a duration of 86.7 to 90 minutes.
- There was no difference in the local anesthetic effects of the topical gel been the scrotum and the tail base. There was no cutaneous anesthesia in piglets receiving Gel with only 0.3% Meloxicam. The topical gel without lidocaine had no local anesthetic activity.
- This research establishes a volume of 1 mL on the scrotum and tail base and a time for castration and tail docking between 30 and 90 minutes.
-
- Objective: To determine the safety of Lidocam for piglets.
- Treatment: The study involved the use of the following treatment groups: Group 1 (4 Males, 4 females): piglets (control) received Lidocam applied topically; Group 2 (4 Males, 4 females): piglets (nominal dose) receive 1 Lidocam gel applied topically; Group 3 (4 Males, 4 females): piglets (3X) received 3 mL L/M gel applied topically; Group 4 (4 Males, 4 females): piglets (nominal) received 1 mL L/M gel applied orally (in case animals lick product off each other). All animals were treated daily for 3 days.
- Data Collection: Blood was collected for hematology and clinical chemistry (day—2), 0, 1, 2, 3. Animals were clinically examined on days—2 through 3. Electrocardiograms were performed on each animal to determine if there was a toxic cardiac effect of Lidocam. All animals were observed for adverse clinical signs daily. On day 3 a complete post mortem was conducted on all animals. Gross and histopathology was performed.
- There are limited literature reports on the toxicity of lidocaine to piglets. The toxicity data in the literature primarily comes from human or laboratory animal data.
- Accidental direct intravascular injection during performance of high-volume peripheral nerve block or epidural anesthesia with a local anesthetic causes systemic toxicity owing to an excess plasma concentration of the drug. Less often, absorption of the local anesthetic from the injection site results in an excess plasma concentration. The extent of systemic absorption depends on: (a) the dose administered into the tissue, (b) the vascularity of the injection site, (c) the presence of adrenalin (epinephrine) in the solution, and (d) physiochemical properties of the drug (3). The CNS and cardiovascular systems affected. Local anesthetics decrease the electrical activity of excitable cells by inhibiting the conductance of sodium channels. At low doses, all local anesthetics are effective anticonvulsants, which also have sedative effects. As the plasma level rises, excitation of the CNS occurs. Toxic responses in the cardiovascular system occur when anesthetics are at higher levels in the blood compared with the levels that cause toxic responses in the CNS.
- Topical Lidocaine toxicity has had remarkable few reports of adverse events. To date systemic toxicity have been reported in humans receiving topical local anesthetics. These have been reported with the use of excessive product over large dermal areas (24).
- In dogs lidocaine toxicity causes a decrease in QT interval but no change in PT and heart rate (25). Newborn piglet receiving intravenous lidocaine did not have any cardiovascular effects but seizures were induced with high dosages (26).
- Clinical Observations: There were no abnormal clinical signs associated with the use of both topical (1X, 2X, 3X) and oral meloxicam. There were no abnormal clinical signs of neurological, gastrointestinal or cardiovascular toxicity. All piglets were active and nursing throughout the study. There was no evidence of dermal irritation (reddening) or behaviors associated with dermal irritation (scratching, biting). This supports the safety of Lidocam Topical Gel.
- Body Weight and Feeding Behavior: There was no difference in weight gain among the treatment groups. It was a surprise the there was a trend for treated animals to gain more weight over the 5 day period than controls. This supports the safety of Lidocam Topical Gel.
- Gross Pathology: There were no abnormal gross pathology observations associated with the use of both topical (1X, 2X, 3X) and oral meloxicam. Gastrointestinal ulceration would be the expected consistent pathological associated with NSAIDs. In spite of a careful examination of the GI tract there was no evidence of damage that has been reported with NSAIDs. This supports the safety of Lidocam Topical Gel.
- Lidocam Topical Gel (4% lidocaine-0.3% meloxicam) is safe for piglets when provided at
- A. 1X=1 mL Lidocam gel on tail+1 mL Lidocam gel on scrotum or rump area;
- B. 2X=2 mL Lidocam gel on tail+2 mL Lidocam gel on scrotum or rump area;
- C. 3X=3 mL Lidocam gel on tail+3 mL Lidocam gel on scrotum or rump area;
- D. 1X OT=1 mL Lidocam gel on tail+1 mL Lidocam gel on scrotum or rump area and 2 mL oral Lidocam;
- E. Control=1 mL Control gel (no active) on tail+1 mL Control gel (no active) on scrotum or rump area.
- This is based upon the clinical observation, weight changes, electrocardiographic recordings, clinical pathology, gross pathology and histopathology.
-
- Objective: To establish a tissue withdrawal period for Lidocam.
- Treatment: The study involve the use of the following treatment of 3-9 day piglets (16 males and 16 females) with 1 mL of Lidocam Gel Applied to the tail base and 1 mL applied to the scrotum the scrotum.
- Analysis: Animals were euthanized at times 2 days, 5 days, 7 days and 10 days. The tissues (liver, kidney, muscle, skin) were harvested, homogenized and tissues analyzed for the level meloxicam using and validated HPLC method approved by CFIA. A withdrawal period was obtained from this information.
- All tissue analysis was performed by Silliker, JR Laboratories according to standard operating procedures and CFIA CVDR-M-3025-01. The results of the report are summarized in Table 5. The Limit of detection of >0.1 ppb and the Limit of quantification results of >0.5 ppb.
- The results of the tissue analysis is provided in Table 3.
-
TABLE 3 Meloxicam in Liver, Kidney, Muscle and Fat after administration of Meloxicam Oral Suspension (ppb) (<MDL = less than minimum detection level). Liver Kidney Muscle Skin MRL = MRL = MRL = MRL = VI. ID Sex Day 60 ppb 200 ppb 20 ppb 20 ppb VII. 6 M 2 32.1 98.1 27.5 2160 1 M 2 34.5 87.3 87.3 1900 2 F 2 23.2 34.8 17.9 1020 7 F 2 22.0 55.0 24.6 580 4 F 4 6.2 9.1 8.9 450 8 F 4 4.9 8.3 4.2 646 10 M 4 4.7 8.5 5.1 359 14 M 4 5.5 10.6 5.2 59.1 3 F 7 0.8 8.9 9.1 71.5 5 F 7 0.8 1.6 0.5 71.6 12 M 7 3.3 6.8 2.5 97.3 16 M 7 0.5 1.4 1.7 320 9 F 10 <0.5 <0.5 1.2 20.2 11 F 10 1.7 1.9 1.6 41.1 15 M 10 <0.5 <0.5 1.3 231 13 M 10 0.7 1.7 2.8 71.7 - Following a single treatment of Lidocam Topical Gel to the skin of the scrotum (1 mL) and the skin at the base of the tail (1 mL) the following observations were obtained:
- Liver: The Meloxicam concentrations in the liver were below the Maximum residue limit (MRL) of 60 ppb at 2 days post treatment.
- Kidney: The Meloxicam concentrations in the kidney were below the Maximum residue limit (MRL) of 200 ppb at 2 days post treatment.
- Muscle: The Meloxicam concentrations in muscle was below the Maximum residue limit
- (MRL) of 20 ppb at 4 days post treatment.
- Skin: The Meloxicam concentrations in the skin was below the Maximum residue limit (MRL) of 20 ppb at greater than 10 days post treatment. Additional pigs will be required to obtain a withdrawal time.
-
- Objective: To determine the efficacy of Lidocam in controlling pain and inflammation following castration.
- Treatment: At 3-7 d of age (±1 d), male pigs (approx. 2.0 kg) were allocated to 2 Treatment groups (n=30/treatment). One mL of Lidocam gel (group 1 treatment) or control 1 mL sham gel (containing no analgesic/anesthesia) was applied to the scrotum. After 30 min, piglets were castrated.
- Electrocutaneous Stimulation Prior to Castration electrocutaneous stimulation of the surgical site was performed and the reaction scored. Electrocutaneous stimulation was also performed at the surgical site at times 3 hours and 24 hours after castration. This measured the short term and long term effects of Lidocam.
- Physiological Response: At times—1 hr, 3 hr and 24 hr after castration a 1 mL blood sample were collected for blood cortisol and Substance P levels.
- Behaviour Response: All pigs will be returned to their home pen at the same time and the behavior of individual pigs will be recorded using 1-min scan samples (direct observations) for the first 30 min after processing, and then at time intervals 90 min.
- Observations included, lying with contact, lying without contact, Nursing, sitting, standing, walking.
- Stress Vocalizations: Vocalizations will be recorded during the castration procedure. A microphone was used to record vocalizations before and during administration of all treatments in both the physiology and behavior experiments. Vocalizations were analyzed using an automatic stress call monitoring system (STREMODO, Forschungsinstitut für die Biologie landwirtschaftlicher Nutztiere, Dummerstorf, Germany). The STREMODO system is described in detail by Schön et al. (2004). Briefly, the system calculates the percentage of stress (high-frequency) vocalizations emitted by the pigs within 10-s periods and differentiates between the high-frequency sounds emitted by the pig and high frequency background sounds.
- Body Weight, Wound Healing and Inflammation: All pigs were weighed prior to treatment, day 7 and day 14. All pigs were observed and wound healing was scored to assess any detrimental effects (e.g. abscesses) caused by any of the castration alleviation methods every second day for 14 d after castration. Castration wounds were scored from 1 to 6, with 6 being a bloody wound with no scab to 1 being completely healed. Inflammation was scored from 1 to 6, with 6 being severe inflammation to 1 being no inflammation.
- Results: The data was collected and analyzed. This is summarized in Table 4.
-
TABLE 4 Summary of Efficacy data from piglets that were castrated Treatment Variable Time Control (Lidocam) P Value Electrocutaneous Stimulation 30 min 1.83 ± 0.15 0.23 ± 0.08 <0.0001 (Score) 3 hr 1.61 ± 0.17 0.17 ± 0.07 <0.0001 24 hr 1.61 ± 0.16 0.44 ± 0.11 <0.0001 Electrocutaneous Stimulation 30 min 2 23 <0.0001 (Number No Reaction to Stimulus) 3 hr 2 23 <0.0001 24 hr 4 17 <0.0001 Stress Maximum 30 min 11.10 ± 2.94 5.67 ± 1.51 0.0104 Vocalization Mean 30 min 0.065 ± 0.01 0.031 ± 0.008 0.0104 Duration 30 min 1.17 ± 0.30 0.57 ± 0.15 0.0104 Body Weight (Kg) Day 0 2.33 ± 0.07 2.25 ± 0.07 0.8778 Day 6 3.22 ± 0.13 3.43 ± 0.15 0.0705 Day 13 4.44 ± 0.15 4.85 ± 0.13 0.0052 Plasma Cortisol T = −1 hr 5.84 ± 0.13 5.99 ± 0.11 0.4213 Ln (pg/mL) T = 3 hr 6.08 ± 0.15 5.82 ± 0.14 0.2140 T = 24 hr 5.99 ± 0.16 5.28 ± 0.13 0.1695 Plasma Substance P T = −1 hr 6.66 ± 0.11 6.67 ± 0.12 0.9158 Ln (pg/mL) T = 3 hr 6.66 ± 0.12 6.46 ± 0.12 0.2339 T = 24 hr 6.08 ± 0.13 5.97 ± 0.16 0.777 Behavior (lying with Contact) T = 2 hr 13.03 ± 2.55 13.5 ± 3.15 0.8222 (Min in 30 min observation) T = 4 hr 19.53 ± 2.23 20.3 ± 2.19 0.4312 Wound Healing T = 0 15.91 ± 0.68 15.26 ± 0.52 >0.05 (Right Scrotum) T = 24 hr 16.17 ± 0.78 16.06 ± 0.62 >0.05 (mm) T = 6 day 6.40 ± 0.75 7.42 ± 0.57 >0.05 T = 13 day 0.00 ± 0.00 0.00 ± 0.00 >0.05 Wound Healing T = 0 15.32 ± 0.71 16.30 ± 0.73 >0.05 (Left Scrotum) T = 24 hr 15.33 ± 0.81 15.97 ± 0.95 >0.05 (mm) T = 6 day 6.58 ± 0.66 7.76 ± 0.66 >0.05 T = 13 day 0.00 ± 0.00 0.00 ± 0.00 >0.05 - Lidocam acted to reduce pain at the time of the castration procedure (reduced reaction to electrocutaneous stimulation and stress vocalization). Plasma cortisol and substance P were not significantly reduced but there was a trend for reduced levels in Lidocam treated animals. Behaviors were not different but due to multiple data collections they could only be observed for 30 minutes. Lidocam resulted in increased body weights at 2 weeks following castration. Lidocam did not impair would healing.
- The same study as described above was conducted but 1 mL gel was applied to the tail base and tail docking was performed. The data was collected and analyzed. This is summarized in Table 5
-
TABLE 5 Summary of Efficacy data from piglets that were tail docked Treatment Variable Time Control (Lidocam) P Value Electrocutaneous Stimulation 30 min 0.77 ± 0.15 0.30 ± 0.11 0.0146 (Score) 3 hr 0.67 ± 0.14 0.53 ± 0.14 0.4117 24 hr 0.97 ± 0.18 0.11 ± 0.13 0.1371 Electrocutaneous Stimulation 30 min 14 23 <0.0001 (Number No Reaction to Stimulus) 3 hr 15 19 >0.05 24 hr 13 16 >0.05 Stress Maximum 30 min 11.10 ± 2.94 5.67 ± 1.51 0.0890 Vocalization Mean 30 min 0.065 ± 0.01 0.031 ± 0.008 0.090 Duration 30 min 1.17 ± 0.30 0.57 ± 0.15 0.090 Body Weight Day 0 2.33 ± 0.07 2.25 ± 0.07 0.422 (Kg) Day 6 3.22 ± 0.13 3.43 ± 0.15 0.3064 Day 13 4.44 ± 0.15 4.85 ± 0.13 0.0905 Plasma Cortisol T = −1 hr 5.84 ± 0.13 5.99 ± 0.11 0.4213 Ln (pg/mL) T = 3 hr 6.08 ± 0.15 5.82 ± 0.14 0.1695 T = 24 hr 5.99 ± 0.16 5.28 ± 0.13 0.0619 Plasma Substance P T = −1 hr 6.66 ± 0.11 6.67 ± 0.12 0.9154 (Ln pg/mL) T = 3 hr 6.66 ± 0.12 6.46 ± 0.12 0.2339 T = 24 hr 6.08 ± 0.13 5.97 ± 0.16 0.6034 Behavior (lying with Contact) T = 2 hr 13.03 ± 2.55 13.5 ± 3.15 0.8722 (Min in 30 min observation) T = 4 hr 19.53 ± 2.23 20.3 ± 2.19 0.5611 Wound Healing T = 0 8.04 ± 0.21 7.85 ± 0.23 0.5390 (mm) T = 24 hr 6.94 ± 0.21 7.09 ± 0.16 0.5486 T = 6 day 6.49 ± 0.23 6.87 ± 0.24 0.2543 T = 13 day 1.20 ± 0.26 1.26 ± 0.27 0.8886 - Lidocam acted to reduce pain at the time of the tail docking procedure (reduced reaction to electrocutaneous stimulation and stress vocalization). Plasma cortisol and substance P were not significantly reduced but there was a trend for reduced levels in Lidocam treated animals. Behaviors were not different but due to multiple data collections they could only be observed for 30 minutes. Lidocam resulted in increased body weights at 2 weeks following tail docking. Lidocam did not impair would healing.
- The same study as described above was conducted but 1 mL gel was applied to the tail base and 1 mL of gel was applied to the scrotum. After 30 minutes tail docking and castrations were performed.
- Results: The data was collected and analyzed. This is summarized in Table 6.
-
TABLE 6 Summary of Efficacy data from piglets that were castrated Treatment Variable Time Control (Lidocam) P Value Electrocutaneous Stimulation (Tail) 30 min 0.93 ± 0.11 0.17 ± 0.11 <0.0001 Score 3 hr 1.00 ± 0.16 0.23 ± 0.14 <0.0001 24 hr 0.75 ± 0.16 0.10 ± 0.13 <0.0001 Electrocutaneous Stimulation 30 min 1.50 ± 0.13 0.57 ± 0.15 <0.0001 (Scrotum) 3 hr 1.87 ± 0.17 0.67 ± 0.14 <0.0001 24 hr 1.62 ± 0.17 0.17 ± 0.07 <0.0001 Electrocutaneous Stimulation (Tail) 30 min 7 25 <0.0001 (Number No Reaction to Stimulus) 3 hr 4 19 <0.0001 24 hr 8 24 <0.0001 Electrocutaneous Stimulation (Scrotum) 30 min 4 16 <0.0001 (Number No Reaction to Stimulus) 3 hr 14 27 <0.0001 24 hr 5 25 <0.0001 Stress Vocalization Maximum 30 min 20.07 ± 3.94 7.13 ± 1.92 0.005 Mean 30 min 0.1143 ± 0.023 0.0399 ± 0.0106 0.005 Duration 30 min 1.80 ± 0.42 0.731 ± 0.191 0.006 Stress Vocalization Maximum 30 min 54.17 ± 2.85 42.21 ± 3.34 0.006 Mean 30 min 0.6265 ± 0.049 0.478 ± 0.048 0.006 Duration 30 min 11.55 ± 0.88 8.607 ± 0.07 0.006 Body Weight Day 0 2.67 ± 0.12 2.70 ± 0.12 0.8722 Day 6 3.76 ± 0.13 4.00 ± 0.14 0.2273 Day 13 5.44 ± 0.14 4.86 ± 0.14 0.0385 Plasma Cortisol T = −1 hr 5.65 ± 0.15 5.49 ± 0.13 0.4411 T = 3 hr 5.93 ± 0.10 5.60 ± 0.09 0.0150 T = 24 hr 6.13 ± 0.08 5.94 ± 0.10 0.1689 Plasma Substance P T = −1 hr 6.22 ± 0.11 6.21 ± 0.11 0.8777 T = 3 hr 7.14 ± 0.12 6.39 ± 0.13 <0.0001 T = 24 hr 5.77 ± 0.13 5.76 ± 0.09 0.9498 Behavior (lying with Contact) T = 2 hr 17.68 ± 2.43 18.8 ± 2.16 0.6732 T = 4 hr 18.36 ± 2.11 19.2 ± 2.18 0.5221 Wound Healing (Tail) T = 0 6.87 ± 0.22 6.81 ± 0.18 >0.05 T = 24 hr 7.50 ± 0.27 7.37 ± 0.19 >0.05 T = 6 day 7.88 ± 0.35 8.00 ± 0.22 >0.05 T = 13 day 2.05 ± 0.27 1.47 ± 0.27 >0.05 Wound Healing (Right Scrotum) T = 0 12.80 ± 0.66 12.89 ± 0.66 >0.05 T = 24 hr 14.95 ± 0.70 13.76 ± 0.69 >0.05 T = 6 day 6.56 ± 0.60 7.78 ± 0.69 >0.05 T = 13 day 0.00 ± 0.00 0.00 ± 0.00 >0.05 Wound Healing (Right Scrotum) T = 0 13.35 ± 0.46 12.06 ± 0.43 >0.05 T = 24 hr 14.48 ± 0.62 13.17 ± 0.55 >0.05 T = 6 day 7.31 ± 0.63 6.46 ± 0.45 >0.05 T = 13 day 0.00 ± 0.00 0.00 ± 0.00 >0.05 - Lidocam acted to reduce pain at the time of the castration and tail docking procedure (reduced reaction to electrocutaneous stimulation and stress vocalization). Plasma cortisol and substance P were significantly reduced. Behaviors were not different but due to multiple data collections they could only be observed for 30 minutes. Lidocam resulted in increased body weights at 2 weeks following tail docking. Lidocam did not impair would healing.
- While the invention has been described in some detail by way of illustration and example, it should be understood that the invention is susceptible to various modifications and alternative forms, and is not restricted to the specific embodiments set forth in the Examples. It should be understood that these specific embodiments are not intended to limit the invention but, on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/302,628 US11964046B2 (en) | 2016-05-17 | 2017-05-17 | Topical composition for the control of pain in animals |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662337824P | 2016-05-17 | 2016-05-17 | |
PCT/IB2017/052910 WO2017199181A1 (en) | 2016-05-17 | 2017-05-17 | Topical composition for the control of pain in animals |
US16/302,628 US11964046B2 (en) | 2016-05-17 | 2017-05-17 | Topical composition for the control of pain in animals |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2017/052910 A-371-Of-International WO2017199181A1 (en) | 2016-05-17 | 2017-05-17 | Topical composition for the control of pain in animals |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/608,613 Continuation US20240216268A1 (en) | 2016-05-17 | 2024-03-18 | Topical composition for the control of pain in animals |
Publications (2)
Publication Number | Publication Date |
---|---|
US20190314271A1 true US20190314271A1 (en) | 2019-10-17 |
US11964046B2 US11964046B2 (en) | 2024-04-23 |
Family
ID=60326538
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/302,628 Active US11964046B2 (en) | 2016-05-17 | 2017-05-17 | Topical composition for the control of pain in animals |
US18/608,613 Pending US20240216268A1 (en) | 2016-05-17 | 2024-03-18 | Topical composition for the control of pain in animals |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/608,613 Pending US20240216268A1 (en) | 2016-05-17 | 2024-03-18 | Topical composition for the control of pain in animals |
Country Status (5)
Country | Link |
---|---|
US (2) | US11964046B2 (en) |
EP (1) | EP3458068B1 (en) |
AU (1) | AU2017267590A1 (en) |
CA (1) | CA3024548A1 (en) |
WO (1) | WO2017199181A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220105029A1 (en) * | 2020-10-07 | 2022-04-07 | The Board Of Trustees Of The University Of Arkansas | Biodegradable chitosan microneedle patch for transdermal delivery for livestock pain management |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022162640A1 (en) * | 2021-02-01 | 2022-08-04 | Massey University | Post-operative pain management |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7166641B2 (en) * | 2002-10-02 | 2007-01-23 | Yung Shin Pharmaceutical Industrial Co., Ltd. | Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same |
DE102004001093A1 (en) * | 2004-01-05 | 2005-07-28 | Liedtke, Rainer K., Dr. | Composition and method of a synergistic topical therapy of neuromuscular pain |
US7666914B2 (en) * | 2004-06-03 | 2010-02-23 | Richlin David M | Topical preparation and method for transdermal delivery and localization of therapeutic agents |
US20080014252A1 (en) * | 2006-07-14 | 2008-01-17 | Delprete Keith | Topical compositions with long lasting effect |
US20110033545A1 (en) * | 2009-08-06 | 2011-02-10 | Absize, Inc. | Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith |
WO2012009542A2 (en) * | 2010-07-14 | 2012-01-19 | Kansas State University Research Foundation | Methods for alleviating chronic pain and improving performance of cattle undergoing dehorning or castration |
US9468599B2 (en) * | 2011-12-27 | 2016-10-18 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
CA2893768C (en) * | 2012-12-07 | 2021-08-24 | Sambria Pharmaceuticals, Llc | Topical preparation for pain relief |
US20150141515A1 (en) * | 2013-11-20 | 2015-05-21 | Firstline Meds, Inc. | Compositions and methods for delivery of nsaid and anesthetic |
WO2015075003A1 (en) * | 2013-11-20 | 2015-05-28 | Boehringer Ingelheim Vetmedica Gmbh | Reducing pain in male animals during castration |
US10213510B2 (en) * | 2014-04-21 | 2019-02-26 | Heron Therapeutics, Inc. | Long-acting polymeric delivery systems |
US10143685B2 (en) * | 2015-01-28 | 2018-12-04 | David Berkheimer | Parenteral and topical compositions for pain |
US20160331735A1 (en) * | 2015-05-11 | 2016-11-17 | Ashraf LATIF | Novel formulations for treatment of pain, neuropathy, wounds, and ulcers |
US20180228747A1 (en) * | 2015-08-05 | 2018-08-16 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Rectal topical lipogel comprising an anesthetic agent and a non-steroidal anti-inflammatory agent for pain relief |
-
2017
- 2017-05-17 WO PCT/IB2017/052910 patent/WO2017199181A1/en unknown
- 2017-05-17 EP EP17798858.1A patent/EP3458068B1/en active Active
- 2017-05-17 US US16/302,628 patent/US11964046B2/en active Active
- 2017-05-17 AU AU2017267590A patent/AU2017267590A1/en not_active Abandoned
- 2017-05-17 CA CA3024548A patent/CA3024548A1/en not_active Abandoned
-
2024
- 2024-03-18 US US18/608,613 patent/US20240216268A1/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220105029A1 (en) * | 2020-10-07 | 2022-04-07 | The Board Of Trustees Of The University Of Arkansas | Biodegradable chitosan microneedle patch for transdermal delivery for livestock pain management |
Also Published As
Publication number | Publication date |
---|---|
CA3024548A1 (en) | 2017-11-23 |
EP3458068A1 (en) | 2019-03-27 |
AU2017267590A1 (en) | 2019-01-17 |
US11964046B2 (en) | 2024-04-23 |
WO2017199181A1 (en) | 2017-11-23 |
EP3458068A4 (en) | 2020-01-22 |
EP3458068B1 (en) | 2024-08-14 |
US20240216268A1 (en) | 2024-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240216268A1 (en) | Topical composition for the control of pain in animals | |
CN1205921C (en) | Long cating injectable formulations contg. hydrogenated castor oil | |
US20030022926A1 (en) | Method for treating neuropathic pain and pharmaceutical preparation therefor | |
RU2670749C2 (en) | Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium | |
RU2095060C1 (en) | Composition showing analgetic or antiinflammatory activity, a method of analgia or treatment of allergic diseases | |
BRPI0720500A2 (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION IN CATTLE AND OTHER ANIMALS | |
Hempstead et al. | Acute cortisol and behavior of dairy goat kids administered local anesthesia, topical anesthesia or systemic analgesia prior to cautery disbudding | |
Lin | Pain management for farm animals | |
Roberts et al. | Innovative pain management solutions in animals may provide improved wound pain reduction during debridement in humans: An opinion informed by veterinary literature | |
Schmitz et al. | Successful implantation of an abdominal aortic blood pressure transducer and radio-telemetry transmitter in guinea pigs—Anaesthesia, analgesic management and surgical methods, and their influence on hemodynamic parameters and body temperature | |
McFadzean et al. | Perioperative pain management in horses | |
Bardell | Managing orthopaedic pain in horses | |
EP3218059A1 (en) | Capsaicinoids for use in treating acral lick granuloma | |
BRPI0902699A2 (en) | Chemical Method for Sexual Sterilization and Libido Elimination in Male Mammals | |
Ding et al. | The antiallodynic action of pregabalin may depend on the suppression of spinal neuronal hyperexcitability in rats with spared nerve injury | |
WO2016152519A1 (en) | External medicine for diffuse plexiform neurofibroma | |
Isaza et al. | Drug delivery to captive Asian elephants-treating Goliath | |
CN110664806B (en) | Fipronil and methoprene dihydric alcohol plastid and preparation method and application thereof | |
Perkins et al. | Nonexperimental xenobiotics: unintended consequences of intentionally administered substances in terrestrial animal models | |
Fekry et al. | Assessment of a multimodal analgesia protocol in goats undergoing claw amputation | |
Mathews | Physiologic and pharmacologic applications to manage neuropathic pain | |
Hammad et al. | Effect of constant rate infusion of xylazine & xylazine-morphine combination on sedation, analgesia and ataxia in horses | |
CN113768908B (en) | Application of benserazide in preparation of anti-animal acariasis medicine | |
Wolfe et al. | Local anesthetics: pharmacology and novel applications | |
RU2604149C2 (en) | Pharmaceutical composition for inflammation and pain and its preparation method (versions) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: EX PARTE QUAYLE ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
STCC | Information on status: application revival |
Free format text: WITHDRAWN ABANDONMENT, AWAITING EXAMINER ACTION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO EX PARTE QUAYLE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
ZAAB | Notice of allowance mailed |
Free format text: ORIGINAL CODE: MN/=. |
|
AS | Assignment |
Owner name: ALBERTA VETERINARY LABORATORIES LTD, CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:OLSON, MERLE;REEL/FRAME:066738/0639 Effective date: 20240301 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |